5Valentine W J, Palmer A J, Lammert M ,et al. Evaluating the long- term cost-effectiveness of liraglutide versus exenatide BID in pa- tients with type 2 diabetes who fail to improve with oral antidiabetic agents[ J]. Clin Ther,2011,33(11) :1698-1712.
6Seino Y, Rasmussen MF, Nishida T, et al. Efficacy and safety of the once-daily human GLP-I analogue, LiragIutide, vs glibene|amide mono-therapy in Japanese patients with type 2 diabetes[J]. Curr Med Res Opin,2010(26) :1013-1022.
7Ryan G J,Foster K T,Jobe L J. Review of the therapeutic uses of liraglutide[ J]. Clin Ther,2011,33(7) :793-811.
8Fakhoury W K, Lereun C, Wright D. A meta-analysis of placebo- controlled clinical trials assessing the efficacy and safety of incre- tion-based medications in patients with 2 diabetes [ J ]. Pharmacolo- gy,2010(86) :44-57.
9Astrup A, Rossner S, Van Gaal L, et al. Effects of Liraglutide in the treatment of obesity : a randomized, double-blind, placebo-controlled study [ J ]. Lancet, 2009 ( 374 ) : 1606-1616.
10Anon UK. Prospective diabetes study 16. Overview of 6 years,therapy of type Ⅱ diabetes: a progressive disease[J]. Diabetes,1995,44(11): 1249-58.
